Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 09 2021
Historique:
received: 05 05 2021
accepted: 13 08 2021
entrez: 3 9 2021
pubmed: 4 9 2021
medline: 16 11 2021
Statut: epublish

Résumé

The function of the amyloid precursor protein (APP) is not fully understood, but its cleavage product amyloid beta (Aβ) together with neurofibrillary tangles constitute the hallmarks of Alzheimer's disease (AD). Yet, imbalance of excitatory and inhibitory neurotransmission accompanied by loss of synaptic functions, has been reported much earlier and independent of any detectable pathological markers. Recently, soluble APP fragments have been shown to bind to presynaptic GABA

Identifiants

pubmed: 34475508
doi: 10.1038/s41598-021-97144-3
pii: 10.1038/s41598-021-97144-3
pmc: PMC8413381
doi:

Substances chimiques

APP protein, human 0
Amyloid beta-Protein Precursor 0
Receptors, Glutamate 0
gamma-Aminobutyric Acid 56-12-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17600

Informations de copyright

© 2021. The Author(s).

Références

Gralle, M. & Ferreira, S. T. Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog. Neurobiol. 82, 11–32 (2007).
pubmed: 17428603 doi: 10.1016/j.pneurobio.2007.02.001
Kang, J. et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733–736 (1987).
doi: 10.1038/325733a0 pubmed: 2881207
De Strooper, B., Iwatsubo, T. & Wolfe, M. S. Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2, a006304 (2012).
pubmed: 22315713 pmcid: 3253024 doi: 10.1101/cshperspect.a006304
Haass, C. Initiation and propagation of neurodegeneration. Nat. Med. 16, 1201–1204 (2010).
pubmed: 21052073 doi: 10.1038/nm.2223
Kuhn, P.-H. et al. ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO J. 29, 3020–3032 (2010).
pubmed: 20676056 pmcid: 2944055 doi: 10.1038/emboj.2010.167
Busche, M. A. & Konnerth, A. Impairments of neural circuit function in Alzheimer’s disease. Philos. Trans. R. Soc Lond. Ser. B Biol. Sci. 371, 20150429 (2016).
doi: 10.1098/rstb.2015.0429
Hsia, A. Y. et al. Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 96, 3228–3233 (1999).
pubmed: 10077666 pmcid: 15924 doi: 10.1073/pnas.96.6.3228
Egan, M. F. et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 378, 1691–1703 (2018).
pubmed: 29719179 pmcid: 6776074 doi: 10.1056/NEJMoa1706441
Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).
pubmed: 29365294 doi: 10.1056/NEJMoa1705971
Salloway, S., Sperling, R. & Brashear, H. R. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease. N. Engl. J. Med. 370, 1459–1460 (2014).
doi: 10.1056/NEJMoa1304839
Alzforum (n.d.). Aducanumab. Retrieved April 25, 2021 https://www.alzforum.org/therapeutics/aducanumab (2020).
Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
pubmed: 27582220 doi: 10.1038/nature19323
Wang, Z. et al. Human brain-derived Aβ oligomers bind to synapses and disrupt synaptic activity in a manner that requires APP. J. Neurosci. 37, 11947–11966 (2017).
pubmed: 29101243 pmcid: 5719975 doi: 10.1523/JNEUROSCI.2009-17.2017
Menéndez, M. Down syndrome, Alzheimer’s disease and seizures. Brain Dev. 27, 246–252 (2005).
pubmed: 15862185 doi: 10.1016/j.braindev.2004.07.008
Deidda, G. et al. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. Nat. Med. 21, 318–326 (2015).
pubmed: 25774849 doi: 10.1038/nm.3827
Palop, J. J. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron 55, 697–711 (2007).
pubmed: 17785178 pmcid: 8055171 doi: 10.1016/j.neuron.2007.07.025
Born, H. A. et al. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer’s disease. J. Neurosci. 34, 3826–3840 (2014).
pubmed: 24623762 pmcid: 3951689 doi: 10.1523/JNEUROSCI.5171-13.2014
Johnson, E. C. B. et al. Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1. Mol. Neurodegener. 15, 53 (2020).
pubmed: 32921309 pmcid: 7489007 doi: 10.1186/s13024-020-00393-5
Freude, K. K., Penjwini, M., Davis, J. L., LaFerla, F. M. & Blurton-Jones, M. Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J. Biol. Chem. 286, 24264–24274 (2011).
pubmed: 21606494 pmcid: 3129207 doi: 10.1074/jbc.M111.227421
Hu, Y. et al. Role of cystatin C in amyloid precursor protein-induced proliferation of neural stem/progenitor cells*. J. Biol. Chem. 288, 18853–18862 (2013).
pubmed: 23671283 pmcid: 3696661 doi: 10.1074/jbc.M112.443671
Hoe, H.-S. et al. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J. Neurosci. 29, 7459–7473 (2009).
pubmed: 19515914 pmcid: 2759694 doi: 10.1523/JNEUROSCI.4872-08.2009
Priller, C. et al. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 26, 7212–7221 (2006).
pubmed: 16822978 pmcid: 6673945 doi: 10.1523/JNEUROSCI.1450-06.2006
Kohli, B. M. et al. Interactome of the amyloid precursor protein APP in brain reveals a protein network involved in synaptic vesicle turnover and a close association with Synaptotagmin-1. J. Proteome Res. 11, 4075–4090 (2012).
pubmed: 22731840 doi: 10.1021/pr300123g
Fanutza, T., Del Prete, D., Ford, M. J., Castillo, P. E. & D’Adamio, L. APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses. Elife 4, e09743 (2015).
pubmed: 26551565 pmcid: 4755753 doi: 10.7554/eLife.09743
Yao, W., Tambini, M. D., Liu, X. & D’Adamio, L. Tuning of Glutamate, But Not GABA, Release by an Intrasynaptic Vesicle APP Domain Whose Function Can Be Modulated by β- or α-Secretase Cleavage. J. Neurosci. 39, 6992–7005 (2019).
pubmed: 31235642 pmcid: 6733572 doi: 10.1523/JNEUROSCI.0207-19.2019
Dawson, G. R. et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90, 1–13 (1999).
pubmed: 10188929 doi: 10.1016/S0306-4522(98)00410-2
Seabrook, G. R. et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38, 349–359 (1999).
pubmed: 10219973 doi: 10.1016/S0028-3908(98)00204-4
Ozawa, S., Kamiya, H. & Tsuzuki, K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54, 581–618 (1998).
pubmed: 9550192 doi: 10.1016/S0301-0082(97)00085-3
Dingledine, R., Borges, K., Bowie, D. & Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev. 51, 7–61 (1999).
pubmed: 10049997
Cousins, S. L. et al. APLP1 and APLP2, members of the APP family of proteins, behave similarly to APP in that they associate with NMDA receptors and enhance NMDA receptor surface expression. J. Neurochem. 133, 879–885 (2015).
pubmed: 25683482 doi: 10.1111/jnc.13063
Cousins, S. L. et al. Amyloid precursor protein 695 associates with assembled NR2A- and NR2B-containing NMDA receptors to result in the enhancement of their cell surface delivery. J. Neurochem. 111, 1501–1513 (2009).
pubmed: 19811606 doi: 10.1111/j.1471-4159.2009.06424.x
Hoe, H.-S. et al. The effects of amyloid precursor protein on postsynaptic composition and activity. J. Biol. Chem. 284, 8495–8506 (2009).
pubmed: 19164281 pmcid: 2659208 doi: 10.1074/jbc.M900141200
Chang, E. H. et al. AMPA receptor downscaling at the onset of Alzheimer’s disease pathology in double knockin mice. Proc. Natl. Acad. Sci. U. S. A. 103, 3410–3415 (2006).
pubmed: 16492745 pmcid: 1413872 doi: 10.1073/pnas.0507313103
Rivera, C. et al. The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 397, 251–255 (1999).
pubmed: 9930699 doi: 10.1038/16697
Sun, D. & Murali, S. G. Na+-K+-2Cl- cotransporter in immature cortical neurons: A role in intracellular Cl- regulation. J. Neurophysiol. 81, 1939–1948 (1999).
pubmed: 10200228 doi: 10.1152/jn.1999.81.4.1939
Ben-Ari, Y. The GABA excitatory/inhibitory developmental sequence: A personal journey. Neuroscience 279, 187–219 (2014).
pubmed: 25168736 doi: 10.1016/j.neuroscience.2014.08.001
Doshina, A. et al. Cortical cells reveal APP as a new player in the regulation of GABAergic neurotransmission. Sci. Rep. 7, 1–14 (2017).
doi: 10.1038/s41598-017-00325-2
Chen, M. et al. APP modulates KCC2 expression and function in hippocampal GABAergic inhibition. Elife 6, 1–26 (2017).
doi: 10.7554/eLife.20142
Hawrot, E. et al. Demonstration of a tandem pair of complement protein modules in GABA(B) receptor 1a. FEBS Lett. 432, 103–108 (1998).
pubmed: 9720905 doi: 10.1016/S0014-5793(98)00794-7
Rice, H. C. et al. Contribution of GABAergic interneurons to amyloid-β plaque pathology in an APP knock-in mouse model. Mol. Neurodegener. 15, 3 (2020).
pubmed: 31915042 pmcid: 6950898 doi: 10.1186/s13024-019-0356-y
Schwenk, J. et al. Modular composition and dynamics of native GABAB receptors identified by high-resolution proteomics. Nat. Neurosci. 19, 233–242 (2016).
pubmed: 26691831 doi: 10.1038/nn.4198
Dinamarca, M. C. et al. Complex formation of APP with GABA(B) receptors links axonal trafficking to amyloidogenic processing. Nat. Commun. 10, 1331 (2019).
pubmed: 30902970 pmcid: 6430795 doi: 10.1038/s41467-019-09164-3
Rice, H. C. et al. Secreted amyloid-b precursor protein functions as a GABA B R1a ligand to modulate synaptic transmission. Science (80-) 363, eaao4827 (2019).
doi: 10.1126/science.aao4827
Mucke, L. et al. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058 (2000).
pubmed: 10818140 pmcid: 6772621 doi: 10.1523/JNEUROSCI.20-11-04050.2000
Mockett, B. G., Richter, M., Abraham, W. C. & Müller, U. C. Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα. Front. Mol. Neurosci. 10, 30 (2017).
pubmed: 28223920 pmcid: 5293819 doi: 10.3389/fnmol.2017.00030
Ooigawa, H. et al. The fate of Nissl-stained dark neurons following traumatic brain injury in rats: Difference between neocortex and hippocampus regarding survival rate. Acta Neuropathol. 112, 471–481 (2006).
pubmed: 16858608 doi: 10.1007/s00401-006-0108-2
Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708–721 (2012).
pubmed: 22541439 pmcid: 3375906 doi: 10.1016/j.cell.2012.02.046
Palop, J. J. & Mucke, L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 17, 777–792 (2016).
pubmed: 27829687 pmcid: 8162106 doi: 10.1038/nrn.2016.141
Fritschy, J.-M. & Panzanelli, P. GABAA receptors and plasticity of inhibitory neurotransmission in the central nervous system. Eur. J. Neurosci. 39, 1845–1865 (2014).
pubmed: 24628861 doi: 10.1111/ejn.12534
Sperk, G., Schwarzer, C., Tsunashima, K., Fuchs, K. & Sieghart, W. GABA(A) receptor subunits in the rat hippocampus I: Immunocytochemical distribution of 13 subunits. Neuroscience 80, 987–1000 (1997).
pubmed: 9284055 doi: 10.1016/S0306-4522(97)00146-2
Malenka, R. C. & Nicoll, R. A. Silent synapses speak up. Neuron 19, 473–476 (1997).
pubmed: 9331339 doi: 10.1016/S0896-6273(00)80362-1
Voigt, T., Opitz, T. & de Lima, A. D. Activation of early silent synapses by spontaneous synchronous network activity limits the range of neocortical connections. J. Neurosci. 25, 4605–4615 (2005).
pubmed: 15872108 pmcid: 6725027 doi: 10.1523/JNEUROSCI.3803-04.2005
Traynelis, S. F. et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 62, 405–496 (2010).
pubmed: 20716669 pmcid: 2964903 doi: 10.1124/pr.109.002451
Ong, J. et al. Short communication CGP 36216 is a selective antagonist at GABA B presynaptic receptors in rat brain. Eur. J. Pharmacol. 415, 191–195 (2001).
pubmed: 11274998 doi: 10.1016/S0014-2999(01)00842-1
Dai, M.-H., Zheng, H., Zeng, L.-D. & Zhang, Y. The genes associated with early-onset Alzheimer’s disease. Oncotarget 9, 15132–15143 (2018).
pubmed: 29599933 doi: 10.18632/oncotarget.23738
Busche, M. A. & Konnerth, A. Neuronal hyperactivity—A key defect in Alzheimer’s disease?. BioEssays 37, 624–632 (2015).
pubmed: 25773221 doi: 10.1002/bies.201500004
Simón, A. M. et al. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Aβ levels. Neurobiol. Dis. 33, 369–378 (2009).
pubmed: 19101630 doi: 10.1016/j.nbd.2008.11.005
Thonberg, H. et al. Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient. BMC Res. Notes 4, 476 (2011).
pubmed: 22044463 pmcid: 3216298 doi: 10.1186/1756-0500-4-476
Hooli, B. V. et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78, 1250–1257 (2012).
pubmed: 22491860 pmcid: 3324321 doi: 10.1212/WNL.0b013e3182515972
Cabrejo, L. et al. Phenotype associated with APP duplication in five families. Brain 129, 2966–2976 (2006).
pubmed: 16959815 doi: 10.1093/brain/awl237
Menendez, M. Down syndrome, Alzheimer’s disease and seizures. Brain Dev. 27, 246–252 (2005).
pubmed: 15862185 doi: 10.1016/j.braindev.2004.07.008
Pan, H. et al. Amyloid β is not the major factor accounting for impaired adult hippocampal neurogenesis in mice overexpressing amyloid precursor protein. Stem Cell Rep. 7, 707–718 (2016).
doi: 10.1016/j.stemcr.2016.08.019
Puzzo, D. et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 14537–14545 (2008).
pubmed: 19118188 pmcid: 2673049 doi: 10.1523/JNEUROSCI.2692-08.2008
Anni, D. et al. Aβ1-16 controls synaptic vesicle pools at excitatory synapses via cholinergic modulation of synapsin phosphorylation. Cell. Mol. Life Sci. 78, 4973–4992 (2021).
pubmed: 33864480 pmcid: 8233295 doi: 10.1007/s00018-021-03835-5
Pousinha, P. A. et al. The amyloid precursor protein C-terminal domain alters CA1 neuron firing, modifying hippocampus oscillations and impairing spatial memory encoding. Cell Rep. 29, 317-331.e5 (2019).
pubmed: 31597094 doi: 10.1016/j.celrep.2019.08.103
Levenga, J. et al. Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol. Commun. 1, 34 (2013).
pubmed: 24252661 pmcid: 3893396 doi: 10.1186/2051-5960-1-34
Sieghart, W. & Sperk, G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2, 795–816 (2002).
pubmed: 12171572 doi: 10.2174/1568026023393507
Whiting, P. J. P. J. GABA-A receptor subtypes in the brain: A paradigm for CNS drug discovery?. Drug Discov. Today 8, 445–450 (2003).
pubmed: 12801796 doi: 10.1016/S1359-6446(03)02703-X
Limon, A., Reyes-Ruiz, J. M. & Miledi, R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. U. S. A. 109, 10071–10076 (2012).
pubmed: 22691495 pmcid: 3382476 doi: 10.1073/pnas.1204606109
Opsomer, R. et al. Amyloid precursor protein (APP) controls the expression of the transcriptional activator neuronal PAS domain protein 4 (NPAS4) and synaptic GABA release. eNeuro 7, 1–18 (2020).
doi: 10.1523/ENEURO.0322-19.2020
Collinson, N. et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABA A receptor. J. Neurosci. 22, 5572–5580 (2002).
pubmed: 12097508 pmcid: 6758233 doi: 10.1523/JNEUROSCI.22-13-05572.2002
Sur, C., Fresu, L., Howell, O., McKernan, R. M. & Atack, J. R. Autoradiographic localization of alpha5 subunit-containing GABAA receptors in rat brain. Brain Res. 822, 265–270 (1999).
pubmed: 10082908 doi: 10.1016/S0006-8993(99)01152-X
Löw, K. et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131–134 (2000).
pubmed: 11021797 doi: 10.1126/science.290.5489.131
Kaupmann, K. et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683–687 (1998).
pubmed: 9872317 doi: 10.1038/25360
Guetg, N. et al. The GABAB1a isoform mediates heterosynaptic depression at hippocampal mossy fiber synapses. J. Neurosci. 29, 1414–1423 (2009).
pubmed: 19193888 pmcid: 6666076 doi: 10.1523/JNEUROSCI.3697-08.2009
Chalifoux, J. R. & Carter, A. G. GABAB receptors modulate NMDA receptor calcium signals in dendritic spines. Neuron 66, 101–113 (2010).
pubmed: 20399732 pmcid: 2861500 doi: 10.1016/j.neuron.2010.03.012
Guetg, N. et al. NMDA receptor-dependent GABAB receptor internalization via CaMKII phosphorylation of serine 867 in GABAB1. Proc. Natl. Acad. Sci. U. S. A. 107, 13924–13929 (2010).
pubmed: 20643921 pmcid: 2922270 doi: 10.1073/pnas.1000909107
Terunuma, M., Vargas, K. J., Wilkins, M. E., Ramírez, O. A. & Jaureguiberry-bravo, M. Prolonged activation of NMDA receptors promotes dephosphorylation and alters postendocytic sorting of GABA B receptors. PNAS 107, 13918–13923 (2010).
pubmed: 20643948 pmcid: 2922229 doi: 10.1073/pnas.1000853107
Al Abed, A. S. et al. Age-related impairment of declarative memory: linking memorization of temporal associations to GluN2B redistribution in dorsal CA1. Aging Cell 19, e13243 (2020).
pubmed: 33009891 pmcid: 7576225 doi: 10.1111/acel.13243
Migaud, M. et al. Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 396, 433–439 (1998).
pubmed: 9853749 doi: 10.1038/24790
Garcia-Alvarez, G. et al. Impaired spatial memory and enhanced long-term potentiation in mice with forebrain-specific ablation of the Stim genes. Front. Behav. Neurosci. 9, 180 (2015).
pubmed: 26236206 pmcid: 4500926 doi: 10.3389/fnbeh.2015.00180
Pineda, V. V. et al. Removal of G(ialpha1) constraints on adenylyl cyclase in the hippocampus enhances LTP and impairs memory formation. Neuron 41, 153–163 (2004).
pubmed: 14715142 doi: 10.1016/S0896-6273(03)00813-4
Taylor, C. J. et al. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol. Dis. 31, 250–260 (2008).
pubmed: 18585048 doi: 10.1016/j.nbd.2008.04.011
Ring, S. et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 7817–7826 (2007).
pubmed: 17634375 pmcid: 6672885 doi: 10.1523/JNEUROSCI.1026-07.2007
Larson, J. & Munkácsy, E. Theta-burst LTP. Brain Res. 1621, 38–50 (2015).
pubmed: 25452022 doi: 10.1016/j.brainres.2014.10.034
Richter, M. C. et al. Distinct in vivo roles of secreted APP ectodomain variants APPsα and APPsβ in regulation of spine density, synaptic plasticity, and cognition. EMBO J. 37, 2018 (2018).
doi: 10.15252/embj.201798335
Wang, B. et al. The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons. J. Neurosci. 34, 13314–13325 (2014).
pubmed: 25274811 pmcid: 4180470 doi: 10.1523/JNEUROSCI.2848-14.2014
Lee, K. J. et al. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Neuroscience 169, 344–356 (2010).
pubmed: 20451588 doi: 10.1016/j.neuroscience.2010.04.078
Kleschevnikov, A. M. et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J. Neurosci. 32, 9217–9227 (2012).
pubmed: 22764230 pmcid: 3411326 doi: 10.1523/JNEUROSCI.1673-12.2012
Lepannetier, S. et al. Activation of TRPC1 channel by metabotropic glutamate receptor mGluR5 modulates synaptic plasticity and spatial working memory. Front. Cell. Neurosci. 12, 1–19 (2018).
doi: 10.3389/fncel.2018.00318
Boucherie, C. et al. Neural progenitor fate decision defects, cortical hypoplasia and behavioral impairment in Celsr1-deficient mice. Mol. Psychiatry 23, 723–734 (2018).
pubmed: 29257130 doi: 10.1038/mp.2017.236
Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47–60 (1984).
pubmed: 6471907 doi: 10.1016/0165-0270(84)90007-4
Anderson, W. W. & Collingridge, G. L. Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions. J. Neurosci. Methods 162, 346–356 (2007).
pubmed: 17306885 doi: 10.1016/j.jneumeth.2006.12.018

Auteurs

Anna Kreis (A)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium.

Jana Desloovere (J)

Faculty of Medicine and Health Sciences, Universiteit Gent, C. Heymanslaan 10, 9000, Gent, Belgium.

Nuria Suelves (N)

Alzheimer Dementia Group, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53, 1200, Brussels, Belgium.

Nathalie Pierrot (N)

Alzheimer Dementia Group, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53, 1200, Brussels, Belgium.

Xavier Yerna (X)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium.

Farah Issa (F)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium.

Olivier Schakman (O)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium.

Roberta Gualdani (R)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium.

Marie de Clippele (M)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium.

Nicolas Tajeddine (N)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium.

Pascal Kienlen-Campard (P)

Alzheimer Dementia Group, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53, 1200, Brussels, Belgium.

Robrecht Raedt (R)

Faculty of Medicine and Health Sciences, Universiteit Gent, C. Heymanslaan 10, 9000, Gent, Belgium.

Jean-Noël Octave (JN)

Alzheimer Dementia Group, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53, 1200, Brussels, Belgium.

Philippe Gailly (P)

Laboratory of Cell Physiology, Institute of Neuroscience, Université Catholique de Louvain, av. Mounier 53/B1.53.17, 1200, Brussels, Belgium. philippe.gailly@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH